Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26

On October 25, 2022 Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) targeting oncology and immuno-dysregulated diseases, reported that Chief Executive Officer Ilya Rachman, MD, PhD, and Chief Financial Officer Gabriel Morris will present a company overview and milestones achieved to enable kick-off of 2 IMX-110 clinical trials at the ThinkEquity Conference at the Mandarin Oriental Hotel in New York, New York on Wednesday, October 26, 2022 at 2:00 PM ET (Press release, Immix Biopharma, OCT 25, 2022, View Source [SID1234622336]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation date and time: October 26, 2022, 2:00 PM ET
View the live presentation: View Source
Presentation Topic: ImmixBio Milestones Achieved to Enable Kick-off of 2 IMX-110 Clinical Trials
A live webcast of the presentation will be available on the Events & Presentations page located within the Investor Relations section of the ImmixBio website at View Source for approximately 90 days following the presentation.

"I am pleased with the level of investor interest in Immix Biopharma after we announced in October that IMX-110 clinical trial data is expected to be released on a rolling basis beginning in Q1 2023," said Ilya Rachman, MD, PhD. "Since then, we have fielded additional inbound industry interest in ImmixBio. We are especially excited about our upcoming combination trial of IMX-110 with BeiGene / Novartis’ anti-PD-1, tislelizumab. I am looking forward to presenting milestones we have achieved to enable kick-off of 2 IMX-110 clinical trials at the upcoming ThinkEquity conference."